Thursday 22 Apr 2021, 5.30pm - via livestream
Thursday 29 Apr 2021, 5.30pm - via livestream
Thursday 6 May 2021, 5.30pm - via livestream
Thursday 13 May 2021, 5.30pm - via livestream
Thursday 20 May 2021, 5.30pm - via livestream
A broad introduction to the principles of paediatric radiotherapy along with a focus on specific diagnoses.
This event is in collaboration with the Children’s Cancer and Leukaemia Group.
The course is open to a multidisciplinary audience and is intended as a broad introduction to the principles of paediatric radiotherapy along with a focus on specific diagnoses. It will be run remotely via 5 weekly sessions of 90 minutes’ duration from 5.30 to 7pm.
Suitable for nurses (including practice and specialist), allied health professionals (AHPs), medical trainees, advanced nurse practitioners (ANPs) and professions allied to medicine (PAMs).
For almost 5 decades, Elekta has been a leader in precision radiation medicine. Their more than 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter, Facebook and LinkedIn.
Elekta Unity is a state-of-the art MR-linac that is defining a new standard for personalized radiation therapy based on real-time high resolution anatomical and biological MRI at the point-of-care. Unity combines a Philips high-field 1.5T MRI scanner with a best-in-class 7MV linear accelerator and breakthrough online dose replanning software that are fully integrated to enable adaptive radiotherapy and real-time target monitoring.
A pioneer in precision radiation medicine, Elekta develops and supports a range of advanced linear accelerators (linacs) that enable physicians to deliver precise, rapid and patient-specific radiotherapy for individuals with cancer. Elekta’s line of high definition digital accelerators includes the latest generation Versa HD™ – a system designed to treat a spectrum of tumors throughout the body using both conventional and highly sophisticated techniques – as well as the clinically-proven and widely used Elekta Synergy® and Elekta Infinity™ linacs.
Flen Health is an international family-owned company located in Luxembourg, Belgium, the Netherlands, Germany, the UK, Ireland, US and UAE. The company’s success is based on the dedication of its people and its safe and easy-to-use product portfolio which combines innovation with significant progress in skin and wound care and is inspired by its motto ‘live the life you love’.
At Flen Health, they believe investing in innovative healing solutions helps to build a more secure life for everyone. They want to improve the quality of life of people suffering from wounds and skin diseases in a responsible way, by providing added value for patients, patients caregiver, healthcare professionals, health authorities and the environment. Based on patented technologies, Flen Health develops and commercialises effective skin and wound healing solutions for any patient and any wound.
Flen Health’s products are distributed in more than 25 countries worldwide. Current product portfolio: Flamigel®, Flaminal® Hydro, Flaminal® Forte, Flamirins®, extracalm®, Flamigel® RT and Flamigel® Repair + Protect Handgel.
For more information, please visit the Flen Health website.
Sign up to our education events mailing list to be kept up to date with this and future events
© 2023 The Christie NHS Foundation Trust
The Christie Charity